Expansion In Chronic Therapies And Emerging Markets Will Thrive
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
10 Aug 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
₹1,652.50
9.0% undervalued intrinsic discount15 Aug
₹1,504.50
1Y
10.3%7D
3.5%